

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETELY KNOWN</b>		
			Application Number	To Be Assigned <b>10/541270</b>	
			Filing Date		
			First Named Inventor	Monaci, et al.	
			Group Art Unit	1646	
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	ITR0043YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/CK/	E	Bargmann, et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein", Nature, Vol. 319, 16 January 1986, pp. 226-230.
	F	Chartier, et al., "Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination in Escherichia coli", J. of Virology, Vol. 70, No. 7, July 1996, pp. 4805-4810.
	G	Cheever, et al., "Immunity to Oncogenic Proteins", Immunological Reviews, No. 145, 1995, pp. 33-59.
	H	Coussens, et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene", Science, Vol. 230, 6 December 1985, pp. 1132-1139.
	I	Disis, et al., "Oncogenic proteins as tumor antigens", Current Opinion in Immunology, Vol. 8, 1996, pp. 637-642.
	J	Disis, et al., "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer", Advances in Cancer Research, Vol. 71, pp. 343-371, 1997.
	K	Disis, et al., "Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines", J. of Clin. Oncol., Vol. 20, No. 11, pp. 2624-2632, 2002.
	L	Disis, et al., "Cancer Vaccines Targeting the Her2/neu Oncogenic Protein", Seminars in Oncology, Vol. 28, No. 6, Suppl.18, pp. 12-20, December 2001.
	M	Foy, et al., "Vaccination with HER-2/neu DNA or protein subunits protects against growth of a HER-2/neu-expressing murine tumor", Vaccine, Vol. 19, pp. 2598-2606, 2001.
	N	King, et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma", Science, Vol. 229, pp. 974-976, 1985.
	O	Lohrisch, et al., "An Overview of HER2", Seminars in Oncology, Vol. 28, No. 6, Suppl 19, December 2001, pp. 3-11.
	P	Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors", DNA and Cell Biology, Vol. 13, No. 9, 777-792, 1993.
	Q	Press, et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues", Oncogene, Vol. 5, pp. 953-962, 1990.
↓	R	Shih, et al., "Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts", Nature, Vol. 290, 19 March 1981, pp. 261-264.
/CK/	S	Shiver, et al., "Cytotoxic T Lymphocyte and Helper T Cell Responses following HIV Polynucleotide Vaccination", Annals New York Academy of Sciences, Vol. 772, pp. 198-208, 1996.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

## COMPLETELY KNOWN

*(use as many sheets as necessary)*

<b>Application Number</b>	To Be Assigned	10/541270
<b>Filing Date</b>		
<b>First Named Inventor</b>	Monaci, et al.	
<b>Group Art Unit</b>	1646	
<b>Examiner Name</b>		
<b>Attorney Docket Number</b>	ITR0043YP	

## NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner  
Signature**

/Claire Kaufman/

Date Considered

05/14/2007

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

(use as many sheets as necessary)

INFORMATION DISCLOSE  
 OIPE  
 COMMENT BY APPL  
 DEC 20 2005  
 PATENT & TRADEMARK OFFICE  
 many sheets as needed

Sheet

1

of

2

**Application Number**

10/541,270

**Filing Date**

~~July 1, 2005~~ 01/30/2006

**First Named Inventor**

Monaci, et al.

## Group Art Unit

1646

**Examiner Name**

**Kaufman**

Attorney Docket Number

ITR0043YP

[illegible][illegible]

**Examiner  
Signature**

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1448B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/541,270
				Filing Date	July 1, 2005
				First Named Inventor	Monaci, et al.
				Group Art Unit	1646
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	ITR0043YP

[illegible]

Examiner Signature	/Claire Kaufman/	Date Considered	05/14/2007
-----------------------	------------------	--------------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005